Matches in Nanopublications for { <http://bio2rdf.org/drugbank_resource:DB01045_DB06697> ?p ?o ?g. }
Showing items 1 to 4 of
4
with 100 items per page.
- drugbank_resource:DB01045_DB06697 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB01045_DB06697 label "DDI between Rifampicin and Artemether - Oral administration of rifampin, a strong CYP3A4 inducer, with Coartem Tablets resulted in significant decreases in exposure to artemether, dihydroartemisinin (DHA, metabolite of artemether) and lumefantrine by 89%, 85% and 68%, respectively, when compared to exposure values after Coartem Tablets alone. Concomitant use of strong inducers of CYP3A4 such as rifampin, carbamazepine, phenytoin and St. Johnâs wort is contraindicated with Coartem Tablets. [drugbank_resource:DB01045_DB06697]" assertion.
- drugbank_resource:DB01045_DB06697 identifier "drugbank_resource:DB01045_DB06697" assertion.
- drugbank_resource:DB01045_DB06697 title "DDI between Rifampicin and Artemether - Oral administration of rifampin, a strong CYP3A4 inducer, with Coartem Tablets resulted in significant decreases in exposure to artemether, dihydroartemisinin (DHA, metabolite of artemether) and lumefantrine by 89%, 85% and 68%, respectively, when compared to exposure values after Coartem Tablets alone. Concomitant use of strong inducers of CYP3A4 such as rifampin, carbamazepine, phenytoin and St. Johnâs wort is contraindicated with Coartem Tablets." assertion.